{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:15:05Z","timestamp":1793830505302,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease frequently coexist and share pathophysiological manifestations. This study aimed to explore the association between T2DM status and prevalence of liver steatosis and fibrosis, identified using the controlled attenuation parameter and liver stiffness measurement attained via\u00a0liver ultrasound transient elastography.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a cross-sectional analysis of data collected in the National Health and Nutrition Examination Survey for 2017\u20132018. Multivariable logistic regression model was used to evaluate the association between T2DM and prevalence of liver steatosis and fibrosis. Subgroup analyses, stratified by sex age, race, and body mass index (BMI), were further performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 2,780 participants aged\u2009\u2265\u200940\u00a0years enrolled, 749 had T2DM, and 2,031 did not. After adjustment for potential confounders, T2DM was associated with a higher prevalence of liver steatosis (OR\u2009=\u20091.7, 95% CI, 1.3\u20132.1). This T2DM-related prevalence was higher among women (OR\u2009=\u20091.8, 95% CI, 1.3\u20132.5) and in the non-Hispanic Black (OR\u2009=\u20091.8, 95% CI, 1.1\u20133.0), other race (OR\u2009=\u20091.9, 95% CI, 1.2\u20133.0), and BMI\u2009&lt;\u200925\u00a0kg\/m<jats:sup>2<\/jats:sup>(OR\u2009=\u20092.0, 95% CI, 1.1\u20133.8) groups. T2DM was also associated with a significantly higher prevalence of fibrosis (OR\u2009=\u20092.0, 95% CI, 1.5\u20132.7), with this association being more prominent for the other race (OR\u2009=\u20092.9, 95% CI, 1.5\u20135.5) and BMI\u2009&lt;\u200925\u00a0kg\/m<jats:sup>2<\/jats:sup>(OR\u2009=\u20093.3, 95% CI: 1.3\u20138.8) groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings indicated a positive association between T2DM status and prevalence of hepatic steatosis and fibrosis. This association was more prominent for individuals with a BMI\u2009&lt;\u200925\u00a0kg\/m<jats:sup>2<\/jats:sup>and was influenced by race-specific effects.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12902-022-01046-y","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T16:03:46Z","timestamp":1652457826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged\u2009\u2265\u200940\u00a0years"],"prefix":"10.1186","volume":"22","author":[{"given":"Jun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"issue":"1","key":"1046_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1046_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","volume":"5","author":"S Mitra","year":"2020","unstructured":"Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"1046_CR3","doi-asserted-by":"crossref","unstructured":"Lee CH, Lui D, Lam K: Non-alcoholic fatty liver disease and type 2 diabetes - An Update. J Diabetes Invest\u00a02022.","DOI":"10.1111\/jdi.13756"},{"issue":"9","key":"1046_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599\u2013612.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1046_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","volume":"75","author":"P Golabi","year":"2021","unstructured":"Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009\u20132019. J Hepatol. 2021;75(4):795\u2013809.","journal-title":"J Hepatol"},{"key":"1046_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jpeds.2018.11.021","volume":"207","author":"EL Yu","year":"2019","unstructured":"Yu EL, Golshan S, Harlow KE, Angeles JE, Durelle J, Goyal NP, Newton KP, Sawh MC, Hooker J, Sy EZ, et al. Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity. J Pediatr. 2019;207:64\u201370.","journal-title":"J Pediatr"},{"key":"1046_CR7","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez-V\u00e9lez R, Garc\u00eda-Hermoso A, Correa-Rodr\u00edguez M, Izquierdo M: Defining values for controlled attenuation parameter and liver stiffness in youth without liver disease. Pediatr Res\u00a02021.","DOI":"10.1038\/s41390-021-01441-6"},{"key":"1046_CR8","unstructured":"Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruszon-Moran D, Dohrmann SM, Curtin LR: National health and nutrition examination survey: analytic guidelines, 1999\u20132010. Vital Health Stat Ser 2 Data Eval Methods Res2013(161):1\u201324."},{"key":"1046_CR9","doi-asserted-by":"crossref","unstructured":"Kim D, Konyn P, Cholankeril G, Ahmed A: Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan. Clin Gastroenterol Hepatol\u00a02021.","DOI":"10.1016\/j.cgh.2021.06.029"},{"issue":"9596","key":"1046_CR10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453\u20137.","journal-title":"Lancet (London, England)"},{"issue":"Suppl 1","key":"1046_CR11","first-page":"S14","volume":"43","author":"Classification and Diagnosis of Diabetes","year":"2020","unstructured":"Classification and Diagnosis of Diabetes. Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14-s31.","journal-title":"Diabetes Care"},{"issue":"6","key":"1046_CR12","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(6):1717\u201330.","journal-title":"Gastroenterology"},{"key":"1046_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.760985","volume":"8","author":"X Liu","year":"2021","unstructured":"Liu X, Shen H, Chen M, Shao J. Clinical Relevance of Vitamins and Carotenoids With Liver Steatosis and Fibrosis Detected by Transient Elastography in Adults. Front Nutr. 2021;8: 760985.","journal-title":"Front Nutr"},{"key":"1046_CR14","doi-asserted-by":"publisher","first-page":"6638306","DOI":"10.1155\/2020\/6638306","volume":"2020","author":"CM Muzica","year":"2020","unstructured":"Muzica CM, Sfarti C, Trifan A, Zenovia S, Cuciureanu T, Nastasa R, Huiban L, Cojocariu C, Singeap AM, Girleanu I, et al. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Can J Gastroenterol Hepatol. 2020;2020:6638306.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"4","key":"1046_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801.","journal-title":"J Hepatol"},{"issue":"6","key":"1046_CR16","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1210\/jc.2015-1966","volume":"100","author":"P Portillo-Sanchez","year":"2015","unstructured":"Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J Clin Endocrinol Metab. 2015;100(6):2231\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1046_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.773342","volume":"12","author":"W Wu","year":"2021","unstructured":"Wu W, Xiang J, Chen X. Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease. Front Endocrinol. 2021;12: 773342.","journal-title":"Front Endocrinol"},{"issue":"3","key":"1046_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/flgastro-2013-100403","volume":"5","author":"JK Dyson","year":"2014","unstructured":"Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline gastroenterology. 2014;5(3):211\u20138.","journal-title":"Frontline gastroenterology"},{"issue":"2","key":"1046_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.15403\/jgld.2014.1121.252.lsf","volume":"25","author":"I Sporea","year":"2016","unstructured":"Sporea I, Mare R, Lupu\u0219oru R, Sima A, Sirli R, Popescu A, Timar R. Liver Stiffness Evaluation by Transient Elastography in Type 2 Diabetes Mellitus Patients with Ultrasound-proven Steatosis. J Gastrointest Liver Dis. 2016;25(2):167\u201374.","journal-title":"J Gastrointest Liver Dis"},{"issue":"8","key":"1046_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236977","volume":"15","author":"K Chen","year":"2020","unstructured":"Chen K, Sng WK, Quah JH, Liu J, Chong BY, Lee HK, Wang XF, Tan NC, Chang PE, Tan HC, et al. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. PLoS ONE. 2020;15(8): e0236977.","journal-title":"PLoS ONE"},{"issue":"8","key":"1046_CR21","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/jgh.14577","volume":"34","author":"LL Lai","year":"2019","unstructured":"Lai LL, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. J Gastroenterol Hepatol. 2019;34(8):1396\u2013403.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"1046_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2337\/dc20-1997","volume":"44","author":"R Lomonaco","year":"2021","unstructured":"Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, et al. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diab Care. 2021;44(2):399\u2013406.","journal-title":"Diab Care"},{"issue":"2","key":"1046_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2337\/dc20-1778","volume":"44","author":"S Ciardullo","year":"2021","unstructured":"Ciardullo S, Monti T, Perseghin G. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes. Diab care. 2021;44(2):519\u201325.","journal-title":"Diab care"},{"issue":"Suppl 1","key":"1046_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/liv.14846","volume":"41","author":"B Schr\u00f6der","year":"2021","unstructured":"Schr\u00f6der B, Kahl S, Roden M. Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity? Liver Int. 2021;41(Suppl 1):105\u201311.","journal-title":"Liver Int"},{"issue":"1","key":"1046_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"4","key":"1046_CR26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.amjcard.2019.05.035","volume":"124","author":"R Andary","year":"2019","unstructured":"Andary R, Fan W, Wong ND. Control of Cardiovascular Risk Factors Among US Adults With Type 2 Diabetes With and Without Cardiovascular Disease. Am J Cardiol. 2019;124(4):522\u20137.","journal-title":"Am J Cardiol"},{"key":"1046_CR27","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.2147\/DMSO.S268592","volume":"13","author":"X Yao","year":"2020","unstructured":"Yao X, Xu X, Jin F, Zhu Z. The Correlation of Type 2 Diabetes Status with Bone Mineral Density in Middle-Aged Adults. Diab Metab Syndr Obesity Targets Ther. 2020;13:3269\u201376.","journal-title":"Diab Metab Syndr Obesity Targets Ther"},{"issue":"1","key":"1046_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7570\/jomes21062","volume":"31","author":"VGR Gangireddy","year":"2022","unstructured":"Gangireddy VGR, Pilkerton C, Xiang J, Tinajero R, Ashcraft AM. Hepatic Fibrosis and Steatosis in Metabolic Syndrome. J Obesity Metab Syndr. 2022;31(1):61\u20139.","journal-title":"J Obesity Metab Syndr"},{"key":"1046_CR29","doi-asserted-by":"crossref","unstructured":"Heredia NI, Zhang X, Balakrishnan M, Hwang JP, Thrift AP: Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic\/Latinos adults in the U.S. Ethnicity Health 2022. p.\u00a01\u201314.","DOI":"10.1080\/13557858.2022.2027883"},{"issue":"4","key":"1046_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00535-019-01635-0","volume":"55","author":"S Oeda","year":"2020","unstructured":"Oeda S, Takahashi H, Imajo K, Seko Y, Ogawa Y, Moriguchi M, Yoneda M, Anzai K, Aishima S, Kage M, et al. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan(\u00ae) M\/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol. 2020;55(4):428\u201340.","journal-title":"J Gastroenterol"},{"issue":"1","key":"1046_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/2050640616646528","volume":"5","author":"WK Chan","year":"2017","unstructured":"Chan WK, Nik Mustapha NR, Wong GL, Wong VW, Mahadeva S. Controlled attenuation parameter using the FibroScan\u00ae XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. United European Gastroenterol J. 2017;5(1):76\u201385.","journal-title":"United European Gastroenterol J"},{"key":"1046_CR32","unstructured":"Liver Ultrasound Transient Elastography Procedures Manual. Centers for Disease Control and Prevention (2018). Available online at:\u00a0https:\/\/wwwn.cdc.gov\/nchs\/data\/nhanes\/2017-2018\/manuals\/2018_Liver_Ultrasound_Elastography_Procedures_Manual.pdf"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01046-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T14:56:24Z","timestamp":1700578584000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01046-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01046-y","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"8 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics review board of the National Center for Health Statistics approved all NHANES protocols and written informed consents were obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}